Literature DB >> 31750758

Delivery of pemetrexed by magnetic nanoparticles: design, characterization, in vitro and in vivo assessment.

Güliz Ak1,2, Didem Aksu1, Eda Çapkın1, Özge Sarı2, Ilgın Kımız Geboloğlu3, Şenay Hamarat Şanlıer1,2.   

Abstract

Drug-loaded magnetic nanoparticles have been developed because of the advantages of specific drug targeting in cancer treatment. Pemetrexed (PEM) is a multi-targeting antifolate agent that is effective for the treatment of many cancers, for example, non-small cell lung cancer. Here, PEM loaded magnetic O-carboxymethyl chitosan (O-CMC) nanoparticles were prepared to deliver PEM on tumor tissue with an external magnetic field. The modification of chitosan to O-CMC was confirmed by FTIR analysis. Nanoparticle synthesis was performed via ionic gelation method. The diameter of magnetic O-CMC nanoparticles (MCMC) was found to be 130.1 ± 22.96 nm. After PEM loading, diameter was found to be 123.9 ± 11.42 nm. The drug release of PEM loaded MCMC (PMCMC) was slower in physiological medium than in acidic medium. A549-luc-C8 and CRL5807 cell lines were used for MTT test which showed that IC50 values of nanoparticles were lower than PEM. The antitumor efficiency of PMCMC in xenograft tumor model was examined with in vivo imaging system (IVIS) and caliper and with hematological analyses. In vivo studies revealed that PMCMC had targeted antitumor activity in A549-luc-C8-tumor-bearing mice compared to PEM. As a result, it was suggested that PMCMC have great potential for the treatment of non-small cell lung cancer.

Entities:  

Keywords:  A549-luc-C8; O-carboxymethyl chitosan; magnetic targeting; nanoparticle; non-small cell lung cancer; pemetrexed

Mesh:

Substances:

Year:  2019        PMID: 31750758     DOI: 10.1080/10826068.2019.1692220

Source DB:  PubMed          Journal:  Prep Biochem Biotechnol        ISSN: 1082-6068            Impact factor:   2.162


  2 in total

1.  Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway.

Authors:  Quan Chen; Bingbing Wu; Pengfei Ge; Peng Zhang; Xia Chen
Journal:  Dis Markers       Date:  2022-06-25       Impact factor: 3.464

Review 2.  Current role of nanoparticles in the treatment of lung cancer.

Authors:  Eliseo Carrasco-Esteban; José Antonio Domínguez-Rullán; Patricia Barrionuevo-Castillo; Lira Pelari-Mici; Olwen Leaman; Sara Sastre-Gallego; Fernando López-Campos
Journal:  J Clin Transl Res       Date:  2021-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.